MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Summary

This is a single-arm, open-label study of sonrotoclax plus zanubrutinib with MRD-driven treatment duration in patients with previously untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The primary goal of this study is to evaluate the efficacy of MRD-guided zanubrutinib plus sonrotoclax for first-line CLL/SLL treatment.

Timeline

Start

2024-05-30

Primary completion

2030-02-28

Completion

2030-07-30

Drugs

Indications